CO reports personal charges from Bristol Myers Squibb, outside the submitted work. EGFR-IN-3 malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this
Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy
mTORC1 inhibitor